Elimination characteristics of bredinin from patients serum in hemodialysis.
The hemodialysability of bredinin, a new immunosuppressive drug, was investigated in five patients on longterm hemodialysis. Blood samples were collected periodically during and inter-dialysis and measured by high-performance liquid chromatography (HPLC) for bredinin. The half-life (t 1/2) of the elimination phase was 4.8 h in our patients during hemodialysis, a 97% reduction of the 155 h t 1/2 reported in uremic patients. The fraction of drug in the body which is removed by dialysis (f) calculated averaged 0.43. A mean of 43% of the drug in the body was removed during 4-hour hemodialysis. Because of the reduction in elimination t 1/2 and the significant drug removal during dialysis we conclude that bredinin is dialyzable.
D000328:Adult; D002853:Chromatography, Liquid; D005260:Female; D006207:Half-Life; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012263:Ribonucleosides / Q000008:administration & dosage / Q000097:blood*
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine